Physician profile
Ross A Johnston
NPI 1346299633
$1,592.96
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $96.05 · 2021: $91.88 · 2022: $177 · 2023: $444 · 2024: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $269.08 | 2019-2023 | Scopis Ent |
| Regeneron Healthcare Solutions, INC. | $241.77 | 2019-2024 | Dupixent |
| Genzyme Corporation | $206.17 | 2019-2023 | |
| Medtronic, INC. | $138.80 | 2022-2024 | Propel, Pteye Parathyroid Detection System |
| Glaxosmithkline, LLC. | $123.46 | 2019-2024 | Nucala |
| Astrazeneca Pharmaceuticals LP | $108.42 | 2019 | |
| Optinose US, INC. | $93.57 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $91.61 | 2019-2023 | |
| Genentech USA, INC. | $86.77 | 2019-2022 | |
| Alk-Abello, INC | $83.83 | 2019-2020 | |
| Acclarent, INC | $35.14 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $19.65 | 2021 | |
| Ambu INC. | $19.21 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.99 | 2019 | |
| Medtronic USA, INC. | $15.36 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.37 | 2021 | |
| Kaleo, INC. | $14.34 | 2019 | |
| Intersect Ent, INC. | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.